Heron 10-Q: Q3 Revenue $35.3M, $23.4M Cash, Going-Concern Warning Absent CorMedix Deal
HRTX sits 50% above its 52-week low of $0.261.
Summary
Heron's Q3 10-Q shows revenue of $35.3 million (down 7.8%) and $23.4 million of cash, with management flagging substantial going-concern doubt unless the $145 million CorMedix asset sale closes or lenders waive covenants.
Key Events · Earnings and Guidance · HRTX
-
Q3 Revenue Falls 7.8%
Net product sales were $35.3 million versus $38.2 million a year ago; Acute Care grew 22.5% to $15.1 million while Oncology fell 22.2% to $20.1 million.
-
Going-Concern Doubt Disclosed
Management states that absent the Asset Sale closing or a covenant waiver, there is substantial doubt about the ability to continue as a going concern for at least one year from issuance.
-
Thin Cash Against Heavy Debt
Cash, cash equivalents and short-term investments totaled $23.4 million at September 30, 2026, against $91.6 million carrying value of the Hercules facility and $34.4 million of 2031 convertible notes.
-
Covenant Risk Within Twelve Months
The working capital facility's minimum cash, revenue and EBITDA covenants may not be satisfied in the next twelve months without additional funding or the Asset Sale closing; acceleration would also trigger the 2031 notes.
Analysis · HRTX · Life Sciences
The headline numbers were already out this morning, but the full 10-Q carries the part that matters: management says that without the CorMedix asset sale closing or a lender waiver, there is substantial doubt about Heron's ability to continue as a going concern within a year. Cash and short-term investments of $23.4 million sit against $91.6 million of Hercules debt and $34.4 million of 2031 convertible notes, and the working capital facility's minimum cash, revenue and EBITDA covenants may not be met in the next twelve months. The $145 million cash sale to CorMedix, expected to close in the first quarter of 2027 pending a stockholder vote, is now the company's lifeline — and a separate Nasdaq bid-price deficiency with a December 22, 2026 cure deadline adds a second clock.
How filings like this one have moved
In the 30 days to Nov 9, 2026, 47.1% of the 1533 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.29%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, HRTX was trading at $0.39 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.6M. The 52-week trading range was $0.26 to $1.58. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.